首页> Diabetes, obesity & metabolism> Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.

Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.

导出 OA

翻译打印收藏纠错

第一作者： Jianping,Xu

第一单位： Key Laboratory of Endocrinology, Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

作者： Jianping,Xu ^[1] ; Hongwei,Ling ^[2] ; Jianlin,Geng ^[3] ; Investigators ^[4] ; Yanli,Huang ^[5] ; Ying,Xie ^[5] ; Huiping,Zheng ^[5] ; Huikun,Niu ^[5] ; Tianhao,Zhang ^[5] ; Jing,Yuan ^[5] ; Xinhua,Xiao ^[1]

作者单位： Key Laboratory of Endocrinology, Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. ^[1] Department of Endocrinology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. ^[2] Department of Endocrinology, Harrison International Peace Hospital, Hengshui, China. ^[3] Details of the rest investigators can be found in the supporting information, list of investigators. ^[4] CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China. ^[5]

关键词 DBPR108 DPP-4 inhibitor metformin type 2 diabetes